WO2001005366A1 - Sunscreen aerosol composition - Google Patents
Sunscreen aerosol composition Download PDFInfo
- Publication number
- WO2001005366A1 WO2001005366A1 PCT/US2000/019459 US0019459W WO0105366A1 WO 2001005366 A1 WO2001005366 A1 WO 2001005366A1 US 0019459 W US0019459 W US 0019459W WO 0105366 A1 WO0105366 A1 WO 0105366A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- mixtures
- group
- present
- stabilizer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
Definitions
- the present invention relates to sunscreens. More particularly, the present invention relates to sunscreen compositions dispensed in the form of an aerosol product that foams.
- Sunscreen compositions are applied to the skin to protect the skin from the sun's ultraviolet rays that can lead to erythema, a reddening of the skin also known as sunburn.
- Sunlight or ultraviolet radiation in the UV-B range has a wavelength of 290nm to 320nm and is known to be the primary cause of sunburn.
- Ultraviolet rays at a wavelength of 320nm to 400nm, known as UV-A radiation produces tanning of the skin. However, in the process of doing so, the UV-A rays can damage or harm the skin.
- Another long-term effect is premature aging of the skin. This condition is characterized by skin that is wrinkled, cracked and has lost its elasticity.
- sunscreens are typically formulated with the goal of inhibiting skin damage from the sun's rays.
- the sunscreen composition filters or blocks the harmful UV-A and UV-B rays that can damage and harm the skin. It is believed that sunscreen agents accomplish this by absorbing the UV-A and/or UV-B rays.
- sunscreen compositions are oil and water emulsions.
- the UV-absorbing compounds are typically incorporated into the oil phase.
- Sunscreens may also include physical or inorganic metal oxides that block the sun's rays. Titanium dioxide and zinc oxide are commonly used for this purpose.
- SPF sun protection factor
- a third consideration is product feel and how well the product spreads over the skin. Typically, consumers want a product that feels smooth and silky and be applied in a smooth continuous film over the skin. Another factor is the shelf life of the product, which is determined by the chemical and physical stability of the sunscreen composition.
- product form will also play a part since there is a variety of choices such as lotions, gels, creams, sprays, and aerosols that are available. Form preference could ultimately determine whether the consumer decides to purchase the product.
- the unique product forms can be appealing to many consumers who are looking for something different.
- Sunscreens that are made in the form of an aerosol are not commonplace, particularly, aerosols that deliver the product as a foam.
- the present invention in brief summary, is a sunscreen composition that is dispensed as an aerosol product.
- the composition contains a sunscreen agent, an emulsifier, a foam builder/stabilizer, a counterion, and a propellant.
- the sunscreen composition also contains an emollient, a humectant, a preservative/antioxidant, and water.
- the ratio of the foam builder/stabilizer to counterion must be about 1 :4 to about 5:1.2. More preferably, the ratio is about 1 :1 to about 5:1.
- the present invention is a sunscreen composition in the form of an aerosol comprising a sunscreen agent, an emulsifier, a foam builder/stabilizer, a counterion, and a propellant.
- sunscreen agents that can be used in the present invention must be capable of absorbing or blocking the harmful effects of ultraviolet radiation. In addition, they must be non-toxic and non-irritating when applied to the skin. Suitable sunscreen agents include, for example, para- aminobenzoic acid (PABA), benzophenone-1 , benzophenone-2, benzophenone-3, benzophenone-4, benzophenone-6, benzophenone-8, benzophenone-12, methoxycinnamate, ethyl dihydroxypropyl-PABA, glyceryl PABA, homosalate, methyl anthranilate, octocrylene, octyl dimethyl PABA, octyl methoxycinnamate, octyl salicylate, PABA, 2- phenylbenzimidazole-5-sulphonic acid, triethanolamine salicylate, 3-(4- methylbenzylidene)-camphor, red petrolatum, and mixtures thereof.
- PABA para-
- the sunscreen agents may be present in an amount about 1 wt.% to about 40 wt.% of the total weight of the composition of the present invention.
- the total amount of sunscreen agents in the composition will depend upon the sun protection factor (SPF) desired. Normally, the higher the SPF, the greater the total amount of sunscreen agents.
- the sunscreen agents are included at about 4 wt.% to about 30 wt.%.
- An emulsifier is an essential component of the present invention.
- An emulsifier enables two or more immiscible liquids to be combined homogeneously, while increasing the viscosity of the composition.
- Emulsifiers that may be used in the present invention include sorbitan oleate, sorbitan sesquioleate, sorbitan isostearate, sorbitan trioleate, polyglyceryl-3- diisostearate, polyglycerol esters of oleic/isostearic acid, polyglyceryl-6 hexaricinolate, polyglyceryl-4-oleate, polygylceryl-4 oleate/PEG-8 propylene glycol cocoate, oleamide DEA, sodium glyceryl oleate phosphate, hydrogenated vegetable glycerides phosphate and mixtures thereof.
- one or more synthetic polymers may be used as an emulsifier.
- PVP Eicosene copolymer acrylat.es/C-io-C30 alkyl acrylate crosspolymer, acrylates/steareth-20 methacrylate copolymer, PEG-22/dodecyl glycol copolymer, PEG-45/dodecyl glycol copolymer, and mixtures thereof.
- the preferred emulsifiers are PVP Eicosene copolymer, acrylates/C 10 -C 3 o alkyl acrylate crosspolymer, PEG-20 sorbitan isostearate, sorbitan isostearate, and mixtures thereof.
- the one or more emulsifiers are present in a total amount about 0.01 wt.% to about 15 wt.% of the total weight of the composition of the present invention.
- about 0.1 wt.% to about 3 wt.% of emulsifiers are used.
- the composition of the present invention must include a foam builder/stabilizer.
- the preferred foam builder/stabilizer is cetyl phosphate, DEA cetyl phosphate, TEA myristate, TEA stearate, magnesium stearate, sodium stearate, potassium laurate, potassium ricinoleate, sodium cocoate, sodium tallowate, potassium castorate, sodium oleate, and mixtures thereof.
- the foam builder/stabilizer in an amount about 0.1 wt.% to about 5 wt.% must be added to the composition of the present invention.
- the foam builder/stabilizer is present in an amount about 0.1 wt.% to about 3 wt.%.
- Counterions are in the composition of the present invention to neutralize components such as an emulsifier and a foam builders/stabilizer.
- Sodium hydroxide, potassium hydroxide, diethanolamine, triethanolamine, aminomethyl propanol, trisodium ethylenediaminetetraacetic acid, and mixtures thereof, are examples of suitable counterions used in the present invention.
- the preferred counterion is triethanolamine.
- Counterion is present in an amount about 0.01 wt.% to about 8 wt.% in the composition of the present invention. Preferably, counterion is present in an amount about 1 wt.% to about 5 wt.%.
- a critical feature of the present invention is the ratio of the foam builder/stabilizer to counterion. To ensure superior foam quality and integrity, the ratio must be about 1 :4 to about 5:1.2. Preferably, the ratio is about 1 :1 to about 5:1.
- Propellant The propellant must be capable of producing a sufficient pressure for expelling the composition from an aerosol container. Furthermore, the propellant must be non-irritating, non-toxic and compatible with the ingredients used in the composition. Suitable propellants are butane, isobutane, propane, dimethyl ether, dichlorodifluoromethane, tetrafluoromethane, dichlorotetrafluoroethane, chlorodifluoromethane, chlorodifluoroethane, difluoroethane, and mixtures thereof.
- the preferred propellant of the present invention is a blend of isobutane and propane, commonly known as A-46 propellant.
- Propellant is present in the range about 3 wt.% to about 15 wt.% of the present invention. Preferably, the propellant is about 5 wt.% to about 9 wt.%.
- composition of the present invention optionally can have water.
- Water can be present in an amount up to about 80 wt.%, preferably, from 30 wt.% to 70 wt.% of water.
- the present composition may additionally contain one or more emollients.
- An emollient provides a softening or soothing effect on the skin surface and is generally considered safe for topical use. Emollients also help control the rate of evaporation and the tackiness of the composition.
- Preferred emollients include mineral oil, lanolin oil, coconut oil, cocoa butter, olive oil, aloe extracts, jojoba oils, castor oil, fatty acids such as oleic and stearic, fatty alcohols such as cetyl and hexadecyl (ENJAY), diisopropyl adipate, hydroxybenzoate esters, benzoic acid esters of C 9 -C-1 5 alcohols, isononyl iso-nonanoate, alkanes such as mineral oil, silicones such as dimethyl polysiloxane, ethers such as polyoxypropylene butyl ethers and polyoxypropylene cetyl ethers, and C ⁇ 2 -C 15 alkyl benzoates, and mixtures thereof.
- the most preferred emollients are hydroxybenzoate esters, aloe vera, C ⁇ 2 -C 15 alkyl benzoates, and mixtures thereof.
- Emollient is present in an amount about 1 wt.% to about 20 wt.% of the total weight of the composition.
- the preferred amount of emollient is about 2 wt.% to about 15 wt.%, and most preferrably about 4 wt.% to about 10 wt.%.
- Humectants A moistening agent, such as a humectant, may be incorporated into the present invention. Suitable humectants include glycerin, polyethylene glycol, polypropylene glycol, sorbitol, PEG-4, and mixtures thereof.
- One or more humectants are optionally present at about 0.5 wt.% to about 8 wt.% in the present invention. Preferably, about 1 wt.% to about 5 wt.% of humectants may be used.
- titanium dioxide may be added to the composition of the present invention.
- This material is generally considered safe for topical use since it is physiologically inert and has a low degree of irritation and toxicity. It functions by reflecting and absorbing sunlight.
- the titanium dioxide is suspended throughout the composition.
- composition of the present invention may have about 0.5 wt.% to about 10 wt.% of titanium dioxide. Preferably, there is present about 1 wt.% to about 3 wt.% titanium dioxide.
- preservatives/antioxidants may be in the present composition.
- Diazolidinyl urea, iodopropynyl butylcarbamate, vitamin E, vitamin E acetate, vitamin C, butylated hydroxytoluene, methylparaben, and mixtures thereof may be a preservative/antioxidant in the present composition.
- One or more preservatives/antioxidants may be present in an amount about 0.01 wt.% to about 2 wt.% of the total weight of the present invention. Preferably, one or more preservatives/antioxidants are present in an amount about 0.1 wt.% to about 1 wt.%.
- the present invention may include a rheological additive, such as magnesium aluminum silicate, hydroxypropyl cellulose, carbomer, cellulose, guar gum, xanthan gum, bentonite, acrylate copolymers, and mixtures thereof.
- a rheological additive such as magnesium aluminum silicate, hydroxypropyl cellulose, carbomer, cellulose, guar gum, xanthan gum, bentonite, acrylate copolymers, and mixtures thereof.
- the rheological additive assists in building the viscosity of the present invention.
- the rheological additive may optionally be present at about 0.05 wt.% to about 5 wt.% in the composition of the present invention.
- rheological additives Preferably, about 0.1 wt.% to about 2 wt.% of rheological additives are present in the present composition.
- the sunscreen composition of the present invention may also contain optional additives.
- optional additives for instance, a fragrance, colorant, plant extract, absorbent, waterproofing agent, and mixtures thereof may be included.
- the process used to manufacture the present invention must be capable of forming a homogeneous composition that can be sprayed or dispensed from an aerosol can.
- aerosol products are made by filling a concentrate into a can and then filling the can with propellant under vacuum conditions.
- the concentrate of the present invention may be prepared by using techniques and methods well known in the art. In general, ingredients are incorporated by mixing and applying heat if necessary, until the concentrate is uniform and homogeneous. If necessary, the concentrate may be homogenized to ensure homogeneity. The concentrate is then placed in an aerosol can which is later filled with propellant.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU61065/00A AU6106500A (en) | 1999-07-15 | 2000-07-14 | Sunscreen aerosol composition |
| MXPA02000457A MXPA02000457A (en) | 1999-07-15 | 2000-07-14 | Sunscreen aerosol composition. |
| EP00947462A EP1200054A1 (en) | 1999-07-15 | 2000-07-14 | Sunscreen aerosol composition |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14426499P | 1999-07-15 | 1999-07-15 | |
| US60/144,264 | 1999-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2001005366A1 true WO2001005366A1 (en) | 2001-01-25 |
Family
ID=22507819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2000/019459 Ceased WO2001005366A1 (en) | 1999-07-15 | 2000-07-14 | Sunscreen aerosol composition |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1200054A1 (en) |
| AU (1) | AU6106500A (en) |
| CA (1) | CA2313955A1 (en) |
| MX (1) | MXPA02000457A (en) |
| WO (1) | WO2001005366A1 (en) |
Cited By (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030013945A (en) * | 2001-08-10 | 2003-02-15 | 이인혜 | Process for preparing a spray type sunscreen agent |
| WO2003011238A3 (en) * | 2001-07-31 | 2003-08-28 | Merck Patent Gmbh | Sunscreen composition |
| WO2004071479A1 (en) * | 2003-02-12 | 2004-08-26 | Connetics Australia Pty Ltd | Film foaming hydroalcoholic foam |
| WO2006099687A1 (en) * | 2005-03-24 | 2006-09-28 | Ensign Laboratories Pty Ltd | Sunscreen aerosol spray |
| US7138295B2 (en) | 1997-04-04 | 2006-11-21 | Elm Technology Corporation | Method of information processing using three dimensional integrated circuits |
| WO2007002047A1 (en) * | 2005-06-20 | 2007-01-04 | The Procter & Gamble Company | A product release system to atomize cosmetic hair or skin compositions containing uv filters |
| US7176545B2 (en) | 1992-04-08 | 2007-02-13 | Elm Technology Corporation | Apparatus and methods for maskless pattern generation |
| US7193239B2 (en) | 1997-04-04 | 2007-03-20 | Elm Technology Corporation | Three dimensional structure integrated circuit |
| US7385835B2 (en) | 1992-04-08 | 2008-06-10 | Elm Technology Corporation | Membrane 3D IC fabrication |
| US8173108B2 (en) | 2009-11-04 | 2012-05-08 | Conopco, Inc. | Sunscreen composition |
| US8206691B2 (en) | 2009-11-04 | 2012-06-26 | Conopco, Inc. | Sunscreen composition with fatty acid alkanolamides |
| US8840869B2 (en) | 2002-10-25 | 2014-09-23 | Foamix Ltd. | Body cavity foams |
| US8865139B1 (en) | 2009-10-02 | 2014-10-21 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
| US8900553B2 (en) | 2007-12-07 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
| US9050253B2 (en) | 2003-08-04 | 2015-06-09 | Foamix Pharmaceuticals Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US9072667B2 (en) | 2009-07-29 | 2015-07-07 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
| US9101662B2 (en) | 2003-08-04 | 2015-08-11 | Foamix Pharmaceuticals Ltd. | Compositions with modulating agents |
| US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
| US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
| US9492412B2 (en) | 2002-10-25 | 2016-11-15 | Foamix Pharmaceuticals Ltd. | Penetrating pharmaceutical foam |
| US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
| US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US9636405B2 (en) | 2003-08-04 | 2017-05-02 | Foamix Pharmaceuticals Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US9662298B2 (en) | 2007-08-07 | 2017-05-30 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| US9682021B2 (en) | 2006-11-14 | 2017-06-20 | Foamix Pharmaceuticals Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
| US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0791353A1 (en) * | 1996-02-26 | 1997-08-27 | Shiseido Company Limited | Ultraviolet absorbing composition |
-
2000
- 2000-07-14 EP EP00947462A patent/EP1200054A1/en not_active Withdrawn
- 2000-07-14 AU AU61065/00A patent/AU6106500A/en not_active Abandoned
- 2000-07-14 MX MXPA02000457A patent/MXPA02000457A/en unknown
- 2000-07-14 CA CA 2313955 patent/CA2313955A1/en not_active Abandoned
- 2000-07-14 WO PCT/US2000/019459 patent/WO2001005366A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0791353A1 (en) * | 1996-02-26 | 1997-08-27 | Shiseido Company Limited | Ultraviolet absorbing composition |
Cited By (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7479694B2 (en) | 1992-04-08 | 2009-01-20 | Elm Technology Corporation | Membrane 3D IC fabrication |
| US7385835B2 (en) | 1992-04-08 | 2008-06-10 | Elm Technology Corporation | Membrane 3D IC fabrication |
| US7550805B2 (en) | 1992-04-08 | 2009-06-23 | Elm Technology Corporation | Stress-controlled dielectric integrated circuit |
| US7485571B2 (en) | 1992-04-08 | 2009-02-03 | Elm Technology Corporation | Method of making an integrated circuit |
| US7615837B2 (en) | 1992-04-08 | 2009-11-10 | Taiwan Semiconductor Manufacturing Company | Lithography device for semiconductor circuit pattern generation |
| US7176545B2 (en) | 1992-04-08 | 2007-02-13 | Elm Technology Corporation | Apparatus and methods for maskless pattern generation |
| US7223696B2 (en) | 1992-04-08 | 2007-05-29 | Elm Technology Corporation | Methods for maskless lithography |
| US7242012B2 (en) | 1992-04-08 | 2007-07-10 | Elm Technology Corporation | Lithography device for semiconductor circuit pattern generator |
| US7193239B2 (en) | 1997-04-04 | 2007-03-20 | Elm Technology Corporation | Three dimensional structure integrated circuit |
| US8841778B2 (en) | 1997-04-04 | 2014-09-23 | Glenn J Leedy | Three dimensional memory structure |
| US7474004B2 (en) | 1997-04-04 | 2009-01-06 | Elm Technology Corporation | Three dimensional structure memory |
| US7138295B2 (en) | 1997-04-04 | 2006-11-21 | Elm Technology Corporation | Method of information processing using three dimensional integrated circuits |
| US8907499B2 (en) | 1997-04-04 | 2014-12-09 | Glenn J Leedy | Three dimensional structure memory |
| US7504732B2 (en) | 1997-04-04 | 2009-03-17 | Elm Technology Corporation | Three dimensional structure memory |
| WO2003011238A3 (en) * | 2001-07-31 | 2003-08-28 | Merck Patent Gmbh | Sunscreen composition |
| KR20030013945A (en) * | 2001-08-10 | 2003-02-15 | 이인혜 | Process for preparing a spray type sunscreen agent |
| US8840869B2 (en) | 2002-10-25 | 2014-09-23 | Foamix Ltd. | Body cavity foams |
| US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
| US11033491B2 (en) | 2002-10-25 | 2021-06-15 | Vyne Therapeutics Inc. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US10821077B2 (en) | 2002-10-25 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
| US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
| US10322085B2 (en) | 2002-10-25 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US9492412B2 (en) | 2002-10-25 | 2016-11-15 | Foamix Pharmaceuticals Ltd. | Penetrating pharmaceutical foam |
| US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US9713643B2 (en) | 2002-10-25 | 2017-07-25 | Foamix Pharmaceuticals Ltd. | Foamable carriers |
| US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| US9211237B2 (en) | 2003-02-12 | 2015-12-15 | Stiefel Research Australia Pty Ltd | Film foaming hydroalcoholic foam |
| WO2004071479A1 (en) * | 2003-02-12 | 2004-08-26 | Connetics Australia Pty Ltd | Film foaming hydroalcoholic foam |
| US8562959B2 (en) | 2003-02-12 | 2013-10-22 | Stiefel Research Australia Pty Ltd | Film foaming hydroalcoholic foam |
| US9050253B2 (en) | 2003-08-04 | 2015-06-09 | Foamix Pharmaceuticals Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US9101662B2 (en) | 2003-08-04 | 2015-08-11 | Foamix Pharmaceuticals Ltd. | Compositions with modulating agents |
| US9636405B2 (en) | 2003-08-04 | 2017-05-02 | Foamix Pharmaceuticals Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| WO2006099687A1 (en) * | 2005-03-24 | 2006-09-28 | Ensign Laboratories Pty Ltd | Sunscreen aerosol spray |
| WO2007002047A1 (en) * | 2005-06-20 | 2007-01-04 | The Procter & Gamble Company | A product release system to atomize cosmetic hair or skin compositions containing uv filters |
| US9682021B2 (en) | 2006-11-14 | 2017-06-20 | Foamix Pharmaceuticals Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| US9662298B2 (en) | 2007-08-07 | 2017-05-30 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US11103454B2 (en) | 2007-08-07 | 2021-08-31 | Vyne Therapeutics Inc. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US10369102B2 (en) | 2007-08-07 | 2019-08-06 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
| US9549898B2 (en) | 2007-12-07 | 2017-01-24 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
| US9795564B2 (en) | 2007-12-07 | 2017-10-24 | Foamix Pharmaceuticals Ltd. | Oil-based foamable carriers and formulations |
| US8900553B2 (en) | 2007-12-07 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
| US9161916B2 (en) | 2007-12-07 | 2015-10-20 | Foamix Pharmaceuticals Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
| US11433025B2 (en) | 2007-12-07 | 2022-09-06 | Vyne Therapeutics Inc. | Oil foamable carriers and formulations |
| US10213384B2 (en) | 2009-04-28 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| US10588858B2 (en) | 2009-04-28 | 2020-03-17 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| US10363216B2 (en) | 2009-04-28 | 2019-07-30 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| US9072667B2 (en) | 2009-07-29 | 2015-07-07 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
| US11219631B2 (en) | 2009-07-29 | 2022-01-11 | Vyne Pharmaceuticals Inc. | Foamable compositions, breakable foams and their uses |
| US9572775B2 (en) | 2009-07-29 | 2017-02-21 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| US10092588B2 (en) | 2009-07-29 | 2018-10-09 | Foamix Pharmaceuticals Ltd. | Foamable compositions, breakable foams and their uses |
| US10350166B2 (en) | 2009-07-29 | 2019-07-16 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
| US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| US10086080B2 (en) | 2009-10-02 | 2018-10-02 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US10610599B2 (en) | 2009-10-02 | 2020-04-07 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US10238746B2 (en) | 2009-10-02 | 2019-03-26 | Foamix Pharmaceuticals Ltd | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US10265404B2 (en) | 2009-10-02 | 2019-04-23 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
| US10137200B2 (en) | 2009-10-02 | 2018-11-27 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US10322186B2 (en) | 2009-10-02 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US8945516B2 (en) | 2009-10-02 | 2015-02-03 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
| US8871184B2 (en) | 2009-10-02 | 2014-10-28 | Foamix Ltd. | Topical tetracycline compositions |
| US12138311B2 (en) | 2009-10-02 | 2024-11-12 | Journey Medical Corporation | Topical tetracycline compositions |
| US10463742B2 (en) | 2009-10-02 | 2019-11-05 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US10517882B2 (en) | 2009-10-02 | 2019-12-31 | Foamix Pharmaceuticals Ltd. | Method for healing of an infected acne lesion without scarring |
| US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
| US10213512B2 (en) | 2009-10-02 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US8865139B1 (en) | 2009-10-02 | 2014-10-21 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US10821187B2 (en) | 2009-10-02 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
| US10835613B2 (en) | 2009-10-02 | 2020-11-17 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
| US9675700B2 (en) | 2009-10-02 | 2017-06-13 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US10946101B2 (en) | 2009-10-02 | 2021-03-16 | Vyne Therapeutics Inc. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US10967063B2 (en) | 2009-10-02 | 2021-04-06 | Vyne Therapeutics Inc. | Surfactant-free, water-free formable composition and breakable foams and their uses |
| US8992896B2 (en) | 2009-10-02 | 2015-03-31 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US8173108B2 (en) | 2009-11-04 | 2012-05-08 | Conopco, Inc. | Sunscreen composition |
| US8206691B2 (en) | 2009-11-04 | 2012-06-26 | Conopco, Inc. | Sunscreen composition with fatty acid alkanolamides |
| US11324691B2 (en) | 2016-09-08 | 2022-05-10 | Journey Medical Corporation | Compositions and methods for treating rosacea and acne |
| US10849847B2 (en) | 2016-09-08 | 2020-12-01 | Foamix Pharamaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
| US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2313955A1 (en) | 2001-01-15 |
| MXPA02000457A (en) | 2002-07-30 |
| AU6106500A (en) | 2001-02-05 |
| EP1200054A1 (en) | 2002-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1200054A1 (en) | Sunscreen aerosol composition | |
| US6395269B1 (en) | Sunscreen lotion or spray composition | |
| US6190645B1 (en) | Sunscreen for the scalp hair and hair | |
| CA2461126C (en) | Sunscreen compositions | |
| AU2003237369B2 (en) | Sunscreen compositions | |
| EP1594454B1 (en) | Film forming hydroalcoholic foam | |
| US6146618A (en) | Disappearing color sunscreen compositions | |
| CA2526626C (en) | Emulsion base for skin care compositions | |
| EP1866033B1 (en) | Sunscreen aerosol spray | |
| US5989529A (en) | Substantive topical composition | |
| JP3749548B2 (en) | High SPF sunscreen formulation | |
| US5208011A (en) | Ultraviolet resistant sunscreen compositions | |
| WO2002043490A1 (en) | Foaming insect repellent compositions | |
| AU671189B2 (en) | Sunscreen compositions | |
| JP2011506610A (en) | Enhanced photostabilization of abozenzone using phosphate-based emulsifiers in the presence of zinc oxide | |
| CN114630651B (en) | Sunscreen composition with low viscosity | |
| MXPA02001664A (en) | Sunscreen lotion or spray composition | |
| AU2002336539A1 (en) | Sunscreen compositions | |
| AU2006227561B2 (en) | Sunscreen aerosol spray |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/000457 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2000947462 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2000947462 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2000947462 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |